期刊文献+

含乌司他丁肺保护液在心肺转流术中的肺保护作用 被引量:3

Effects of pulmonary protective solution involved ulinastatin on lung function after cardiopulmonary bypass
原文传递
导出
摘要 目的 评价在先心病伴肺动脉高压患儿心肺转流术期间,从肺动脉灌注含乌司他丁的低温肺保护液对肺脏的保护作用。方法选择2005—09—2006—12浙江大学医学院附属儿童医院心胸外科收治的左向右分流先心病伴中重度肺动脉高压的患儿54例,中重度肺动脉高压以肺动脉收缩压/体循环收缩压〉0.45为标准,手术前有感染征像(白细胞〉12000/μL,体温〉38℃,C-反应蛋白〉8mg/L)、过敏史者除外。采用抽签法随机分为三组,各18例,A组为对照组(术中未给予肺保护液),B组在术中经肺动脉灌注不含乌司他丁的低温肺保护液,C组在术中经肺动脉灌注含乌司他丁的低温肺保护液。在开胸后及回ICU后0h,3h,6h,24h(T1-5)五个时点抽取桡动脉血样,测定血浆丙二醛(MDA)、髓过氧化物酶(MPO)浓度;在T1-4计算肺泡-动脉氧分压差(A-aDO2)、肺动态顺应性(Cd)。记录呼吸机辅助通气时间。采用SPSS12.0统计软件对计量指标进行统计分析,资料以均数±标准差(x±s)表示,组间比较用单因素方差分析,组间两两比较用LSD法检验,以P〈0.05为差异具有统计学意义。结果三组患儿回ICU后各时点(BT1-5)MDA、MPO值均较T1升高;与A组相比:B组在T4时点MDA、MPO[分别为(7.66±1.42)pg/mL,(194.2±35.41)U/L]显著降低(P〈0.05),组C在B—B时点MDA[分别为(5.37±1.01)pg/mL,(7.52±0.98)pg/mL,(6.22±0.83)pg/mL]及在T4时点MPO(184.2±35.41)U/L均显著降低;两干预组(B组和C组)各时间点MDA和MPO差异无统计学意义。三组术后A—aD02升高;与A组相比:B组与C组在T3,T4时点小,但C组在T4时点A—aDO2(72.9±23.94)mmHg较组B(89.2±24.28)mmHg低,差异具有统计学意义。三组术后Cd降低;与A组相比:B组在B时点[(0.57±0.16)mL·cmH2O^-1·kg^-1]、C组在T3和T4� Objective To evaluate protective effects of hypothermic pulmonary protective solution with ulinastatin on lung function during cardiopulmonary bypass (CPB) in the patients with congenital heart disease(CHD) and pulmonary hypertension. Method Fifty-four children, who had CHD of left-to-right shunts with moderate-serious pulmonary hypertension, were enrolled. They had been performed with the radical operation under CPB from September 2005 to December 2006 in the Department of Cardiovascular Surgery, Children' s Hospital of Zhejiang University. Moderate-serious pulmonary hypertension was defined as pulmonary-to-systolic pressure ratio 〉 0.45 (Pp/Ps 〉 0.45). Fifty-four children were randomly divided into three groups. Patients in group A (n = 18) didn't receive pulmonary protective solution, and served as control; patients in group B (n =18) were administered with pulmonaryy protective solution without ulinastatin; patients in group C (n = 18) were administered with pulmonary protective solution with ulinastatin. The sewJn concentrations of MDA and MPO were measured at five different time points:pre-operation, 0 h, 3 h, 6 h and 24 h in the intensive care anit (ICU) (T/-5)- Patients' lung functions were monitored at T1 - T4. Tile time of mechanical ventilation was recorded. Results No one died in this study. The mean time of mechanical ventilation was shorter in the group B and group C than that in the group A. The MDA and MPO levels were lower in group B compared with group A at T4. The MDA level at T3 - T5 and the MPO level at T4 was lower in group C than those in group A. There were no significant in MDA and MPO levels between group B and group C at five time point. A-aDO2 was lower in groups B and C than those in group A at T3 and T4, whereas at T4, A-aDO2 was lower in group C than that in group B. Cdyn was higher in group B at T3 and group C at T3 - T4 than those in group A. Cdyn was lower in groups C than that in group B at T4. Conclusions Lung peffusion with hypother
出处 《中华急诊医学杂志》 CAS CSCD 北大核心 2009年第6期594-597,共4页 Chinese Journal of Emergency Medicine
关键词 乌司他丁 心肺转流术 肺保护 先天性心脏病 Ulinastatin Cardiopulmonary bypass Lung protection Congenital heart disease
  • 相关文献

参考文献11

  • 1杨思源主编..小儿心脏病学 第3版[M].北京:人民卫生出版社,2005:643.
  • 2Shahzad GR. The ' dark side' of cardiopuhnonary bypass [ J ]. Eur J Cardiothorac Surg, 2004,25(5) :906-907. 被引量:1
  • 3Roberts KE, McElroy JJ, Wong WP, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease [ J ]. Eur Respir J, 2004,24(3) :371-374. 被引量:1
  • 4Komai H, Yamamoto F, Tanaka K, et al. Increased lung injury in pulmonary hypertensive patients during open heart operations [ J ]. Ann Thrac Surg , 1993,55(5) : 1147-1152. 被引量:1
  • 5de Vroege C,van Oeveren W, van Klarenbosch J, et al. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary, function and the release of inflammatory mediators[J]. Anesth Analg, 2004,98 (6) : 1586-1594. 被引量:1
  • 6Bando K, Pillai R, Cameron DE, et al. Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass [ J ]. J Thorac Cardiovasc Surg, 1990,99 (5) : 873-877. 被引量:1
  • 7Carney DE, Lutz CJ,Picone AL, et al. Soluble tumor necrosis factor receptor prevents post-pump syndrome[ J]. J Surg Res, 1999,83 ( 2 ) : 113- 121. 被引量:1
  • 8Wei B, Liu Y, Wang Q, et al. Lung perfusion with protective solution relieves lung injury in corrections of Tetralogy of Fallot [ J ]. Ann Thrac Surg,2004,77(3) : 918-924. 被引量:1
  • 9Suzuki T, Fukuda T, Ito T, et al. Continuous pulmonary perfusion during cardiopuhnonary bypass prevents lung injury in infants [ J ]. Ann Thrac Surg, 2000,69(2) :602-606. 被引量:1
  • 10Hiyama A, Takeda J, Kotate Y, et al. A human urinaryprotease inhibitor (ulinastatin) inhibits neutrophil extraeellular release of elastase during eardiopulmonary bypass[J]. J Cardiothorae Vase Anesth, 1997, 11(5) :580-584. 被引量:1

二级参考文献12

  • 1Ng CS, Wan S, Yim AP, et al. Pulmonary dysfunction after cardiac surgery. Chest, 2002, 121 (4): 1269-1277. 被引量:1
  • 2Paparclla D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. Eur J Cardiothorac Surg,2002, 21 (2): 232-244. 被引量:1
  • 3Picone AL, Lutz CJ, Finck C, et al. Multiple sequential insults cause post-pump syndrome . Ann Thorac Surg, 1999, 67 (4): 978-985. 被引量:1
  • 4Cremer J, Martin M, Redl H, et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg, 1996, 61 (6):1714-1720. 被引量:1
  • 5Redding GJ. Current concepts in adult respiratory distress syndrome in children. Curr Opin Pediatr, 2001, 13 (3): 261-266. 被引量:1
  • 6Friedman M, Sellke FW, Wang SY, et al. Parameters of pulmonary injury after total or partial cardiopulmonary bypass. Circulation, 1994,90 (5 Pt 2): Ⅰ262-268. 被引量:1
  • 7Asimakopoulos G, Smith PL, Ratnatunga CP, et al. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg, 1999, 68 (3): 1107-1015. 被引量:1
  • 8Gando S, Tedo I. Increased neutrophil elastase in patients with cardiopulmonary arrest: role of elastase inhabitor. Intensive Care Med,1995, 21 (8): 636-640. 被引量:1
  • 9Hiyama A, Takeda J, Kotate Y, et al. A human urinary protease inhibitor (Ulinastatin) inhibits neutrophil extracellular release of elasetase during cardiopulmonary bypass. J Cardiothorac Vasc Anesth,1997, 11 (5): 580-584. 被引量:1
  • 10Sugita T, watarida S, Katsuyama K, et al. Effect of a human urinary protease inhibitor (Ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass. J Cardiovasc Surg (Torino), 2002, 43 (4): 437-440. 被引量:1

共引文献9

同被引文献56

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部